Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo

European Journal of Heart Failure

Volumn 12, Issue 10, 2010, Pages 1042-1050

  Kuipers, Irma ^a   Li, Jiang ^a   Vreeswijk Baudoin, Inge ^a   Koster, Johan ^a   Van Der Harst, Pim ^a   Silljé, Herman H W ^a   Kuipers, Folkert ^a   Van Veldhuisen, Dirk J ^a   Van Gilst, Wiek H ^a   De Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Hypertrophy; Liver X receptor; Metabolism; Myocytes; Pressure; Remodelling

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ENDOTHELIN 1; ISOPROTEIN; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; NEWBORN; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HEART VENTRICLES; HYDROCARBONS, FLUORINATED; HYPERTROPHY, LEFT VENTRICULAR; MICE; MYOCYTES, CARDIAC; ORPHAN NUCLEAR RECEPTORS; RNA, SMALL INTERFERING; SULFONAMIDES;

EID: 77957222438     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq109     Document Type: Article

References (32)

1. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003;65:45-79.
2. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. Acute neurohumoral modulation of diastolic function. Peptides 2009;30:419-425.
3. Van Bilsen M, van Nieuwenhoven FA, van der Vusse GJ. Metabolic xysterols of the failing heart: beneficial or detrimental? Cardiovasc Res 2009;81:420-428.
4. Palmer JN, Hartogensis WE, Patten M, Fortuin FD, Long CS. Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest 1995;95:2555-2564.
5. Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 2004;64:507-515.
6. Molkentin JD, Robbins J. With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure. J Mol Cell Cardiol 2009;46:130-136.
7. Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu Rev Med 2006;57:313-329.
8. Chen R, Liang F, Moriya J, Yamakawa J, Takahashi T, Shen L, Kanda T. Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful? Int J Cardiol 2008;130: 131-139.
9. Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008;18:461-467.
10. Morello F, de Boer RA, Steffensen KR, Gnecchi M, Chisholm JW, Boomsma F, Anderson LM, Lawn RM, Gustafsson JK, Lopez-Ilasaca M, Pratt RE, Dzau VJ. Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest 2005;115:1913-1922.
11. Kuipers I, van der Harst P, Navis G, van Genne L, Morello F, van Gilst WH, van Veldhuisen DJ, de Boer RA. Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system. Hypertension 2008;51:1442-1448.
12. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008;134: 97-111.
13. Chen M, Beaven S, Tontonoz P. Identification and characterization of two alternatively spliced transcript variants of human liver X receptor alpha. J Lipid Res 2005;46:2570-2579.
14. Westenbrink BD, Ruifrok WP, Voors AA, Tilton RG, van Veldhuisen DJ, Schoemaker RG, van Gilst WH, de Boer RA. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovasc Res 2010;87:30-39.
15. Van der Veen JN, Havinga R, Bloks VW, Groen AK, Kuipers F. Cholesterol feeding strongly reduces hepatic VLDL-triglyceride production in mice lacking the liver X receptor alpha. J Lipid Res 2007;48:337-347.
16. Troy BL, Pombo J, Rackley CE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation 1972;45:602-611.
17. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. Role of LXRs in control of lipo-genesis. Genes Dev 2000;14:2831-2838.
18. Bruemmer D, Law RE. Liver x receptors: potential novel targets in cardiovascular diseases. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:533-540.
19. Wu S, Yin R, Ernest R, Li Y, Zhelyabovska O, Luo J, Yang Y, Yang Q. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res 2009;84:119-126.
20. Johansson ME, Wickman A, Skott O, Gan LM, Bergstrom G. Blood pressure is the major driving force for plaque formation in aortic-constricted ApoE2/2 mice. J Hypertens 2006;24:2001-2008.
21. Kuipers I, van der Harst P, Kuipers F, van Genne L, Goris M, Lehtonen JY, van Veldhuisen DJ, van Gilst WH, de Boer RA. Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin- aldosterone system. Lab Invest 2010;90:630-636.
22. Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol 2007;151: 450-456.
23. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris KE, Edelman JM, Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110: 1456-1462.
24. Blaschke F, Leppanen O, Takata Y, Caglayan E, Liu J, Fishbein MC, Kappert K, Nakayama KI, Collins AR, Fleck E, Hsueh WA, Law RE, Bruemmer D. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ Res 2004;95: e110-e123.
25. Wente W, Brenner MB, Zitzer H, Gromada J, Efanov AM. Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells. Endocrinology 2007;148:1843-1849.
26. Komuves LG, Schmuth M, Fowler AJ, Elias PM, Hanley K, Man MQ, Moser AH, Lobaccaro JM, Williams ML, Mangelsdorf DJ, Feingold KR. Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J Invest Dermatol 2002;118:25-34.
27. Vedin LL, Lewandowski SA, Parini P, Gustafsson JA, Steffensen KR. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 2009;30:575-579.
28. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P, El Jamali A, Dietz R, Scheidereit C, Bergmann MW. Requirement of nuclear factor-kappaB in angiotensin II-and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005;111:2319-2325.
29. Frantz S, Hu K, Bayer B, Gerondakis S, Strotmann J, Adamek A, Ertl G, Bauersachs J. Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J 2006;20:1918-1920.
30. Imayama I, Ichiki T, Patton D, Inanaga K, Miyazaki R, Ohtsubo H, Tian Q, Yano K, Sunagawa K. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 2008;51: 1631-1636.
31. Wang YY, Dahle MK, Steffensen KR, Reinholt FP, Collins JL, Thiemermann C, Aasen AO, Gustafsson JA, Wang JE. Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates post-transcriptional TNF-alpha production and p38 MAPK activation in liver macro-phages. Shock 2009;32:548-553.
32. Park HJ, Georgescu SP, Du C, Madias C, Aronovitz MJ, Welzig CM, Wang B, Begley U, Zhang Y, Blaustein RO, Patten RD, Karas RH, Van Tol HH, Osborne TF, Shimano H, Liao R, Link MS, Galper JB. Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. J Clin Invest 2008; 118:259-271.